Advertisement

Picture BioM Forum Translational Medicine 2018 Würzburg Germany iito 600x60px
Document › Details

GlucoMe Ltd.. (2/14/18). "Press Release: GlucoMe to Introduce and Demonstrate Its New Digital Diabetes Clinic at HIMSS18". Yarkona.

Organisation Organisation GlucoMe Ltd.
Products Product GlucoMe Digital Diabetes Clinic (DDC)
  Product 2 HIMSS 2018 Annual Conference and Exhibition (HIMSS18) Las Vegas
Person Person Erickson, John (GlucoMe 201704– EVP General Manager North America before Abbott + JnJ)
     


Digital diabetes platform provider GlucoMe will introduce and demonstrate its new Digital Diabetes Clinic (DDC) at #HIMSS18, March 5-9, 2018 in Las Vegas, booth number 10343.

GlucoMe EVP, General Manager, North America, John Erickson said: "We are very excited to be able to introduce and demonstrate GlucoMe's new digital diabetes clinic at #HIMSS18. The ability to remotely and continuously track a patient's blood glucose and insulin levels enables healthcare professional (HCPs) teams to simultaneously follow the status of thousands of patients in real-time. HCPs can instantly review patient history and treat those in need in a timely manner during an office visit or through a digital visit, in the event the patient is unable to get to the office due to distance or other obstacles. This new approach inspires a huge paradigm shift for global diabetes care and we are proud to be leading the way."

The DCC is a key component of GlucoMe's comprehensive digital diabetes care solution. This cloud-based monitoring and decision support software gives medical professionals unequalled big data insights into real-life patient behavior patterns. Utilizing AI and machine learning for big data analytics, GlucoMe's DDC provides an end-to-end solution that includes data collection, root cause analysis and treatment insights. The DDC integrates with electronic health record software and continuously analyzes clinical data. Along with population management, it enables digital or face-to-face intervention for the right patients at the right time – saving time and money for both healthcare providers and payers.

Current DDC benefits include:

> Snapshots of individual-level patient usage, adherence and treatment effectiveness

> Root cause analysis converting big data into clinical intelligence.

> Care model modification with combined digital and physical visits

> Appropriate specialist intervention at the right time

> Personalized real-time alerts and reminders for patients and healthcare providers

> Interfaces with EMR/EHR systems

> Identification and control of high-risk areas in diabetes management

> Patient, clinic and population management

To schedule a private briefing with management and/or a private demonstration of the solution, please e-mail angelica@glucome.com.


About GlucoMe

GlucoMe is a digital health company developing and marketing a comprehensive digital diabetes care solution that streamlines and simplifies diabetes care for patients, caregivers, healthcare professionals and payers. Based on real-time data and stored patient histories, the solution enables medical teams to continuously monitor and remotely treat up to 10X more patients than possible with standard, face-to-face appointments and to identify the most urgent cases for timely treatment. The system also encourages patients to self-monitor with an affordable connected BGM that, unlike the competition, uses a patented audio connectivity technology that can transfer data to any mobile phone and eliminates patient recording errors. The GlucoMe solution has a CE mark. FDA Marketing Authorization clearance is anticipated in 2018. Several clinical trials of the platform are ongoing worldwide. www.glucome.com

Click here to watch how GlucoMe's solution works.

Follow us on LinkedIn, Facebook and Twitter.


Press Contact

Marjie Hadad
CEO
MH Communications
On behalf of GlucoMe
+972-54-536-5220
marjierhadad@gmail.com

   
Record changed: 2018-08-25

Advertisement

Picture BioM Forum Translational Medicine 2018 Würzburg Germany 600x60px

More documents for GlucoMe Ltd.


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture BioM Forum Translational Medicine 2018 Würzburg Germany 600x60px




» top